

FIRST EASL NAFLD SUMMIT

Target-oriented approach to diagnosis and pharmacotherapy of NASH: a dialogue between academia and industry

9-11 November 2017 – Rome, Italy

Organising committee:

Ali Canbay, Germany

Claus Hellerbrand, Germany

Wing-Kin Syn, United States

Michael Trauner, Austria

Preliminary programme

DAY 1 – Thursday 9 November 2017

- 13:55 – 14:00 *Welcome and introductory remarks*
Michael Trauner, Austria
- 14:00 – 14:30 **State-of-the-Art lecture**
Unmet needs in understanding pathogenesis and management of NAFLD and NASH
Vlad Ratziu, France

1. HEPATIC LIPID METABOLISM AND LIPOTOXICITY AS PROGNOSTIC / THERAPEUTIC TARGET

Chairs: Michael Trauner, Austria

Christopher Day, United Kingdom

- 14:30 – 14:55 *Benefits/perils of promoting lipid combustion or inhibition of lipogenesis (DGAT, SCD, ANGPTL-3 inhibitors) in counteracting lipotoxicity*
Leanne Hodson, United Kingdom
- 14:55 – 15:20 *PNPLA3 and other genetic markers (TM6SF2) for risk stratification*
Quentin Mark Anstee, United Kingdom
- 15:20 – 15:45 *PPAR alpha and/or delta as pharmacological target (including discussion of FGF-21 (PPAR α downstream target) and brown/beige fat as PPAR/FGF21 target)*
Bart Staels, France
- 15:45 – 16:10 *MRI, MR spectroscopy, CAP – does hepatic lipid content/composition matter*
Valérie Vilgrain, France (TBC)
- 16:10 – 16:30 Coffee break and ePoster session 1**

2. INSULIN RESISTANCE, INSULIN AND HORMONAL SIGNALING

Chairs: Helena Cortez-Pinto, Portugal

Philip Newsome, United Kingdom

- 16:30 – 16:55 *Academic overview*
Hannele Yki-Järvinen, Finland
- 15:55 – 17:20 *Insulin sensitizers (metformin, TZDs/PPAR gamma) – in or out (including novel insulin, glucagon, GLP-1 fusion mimetics?)*
Christopher Byrne, United Kingdom
- 17:20 – 17:45 *GLP-1 receptor agonists in diabetes and obesity: A potential in NASH?*
Lotte Knudsen, Denmark
- 17:45 – 18:10 *Vitamin D, thyroid function (the obvious and neglected; including Liver-Directed Thyroid Hormone Receptor- β (THR- β) agonists*
Rebecca Taub, United States

18:10 – 18:40 Coffee break and ePoster session 2

3. OXIDATIVE STRESS, ER STRESS, MITOCHONDRIAL DYSFUNCTION

Chairs: Ali Canbay, Germany

Luca Valenti, Italy

- 18:40 – 19:05 *Academic overview*
Francesc Villaroya, Spain (TBC)
- 19:05 – 19:30 *Targeting oxidative stress and ER stress: more than Vitamin E and UDCA*
Gökhan Hotamisligil, United States (TBC)
- 19:30 – 19:55 *Risk and benefit of pharmacological stimulation of mitochondrial (dys)function*
Michael Roden, Germany

20:00 – 21:00 Cocktail reception and ePoster session 3

DAY 2 – Friday 10 November 2017

4. INFLAMMATION, ADAPTIVE AND INNATE IMMUNITY IN NASH

Chairs: Frank Tacke, Germany

Win-Kin Syn, United States

- 08:30 – 08:55 *Academic overview*
Frank Tacke, Germany
- 08:55 – 09:20 *Industry perspective – inhibitors of CCR2 and 5*
Eric Lefebvre, United States
- 09:20 – 09:45 *Oral immune therapy for NASH: A new class of drugs that target the gut immune system*
Yaron Ilan, Israel
- 09:45 – 10:10 *Role of Inflammasomes in NAFLD*
Fabio Marra, Italy (TBC)
- 10:10 – 10:35 *VAP-1 inhibitors*
Joerg Rippmann
- 10:35 – 10:55 Coffee break and ePoster session 4**

5. APOPTOSIS, MICROPARTICLES

Chairs: Jose Fernandez-Checa, Spain

Helen Reeves, United Kingdom

- 10:55 – 11:20 *Academic overview*
Ali Canbay, Germany
- 11:20 – 11:45 *Caspase inhibitors: academic clinical*
Jose Fernandez-Checa, Spain
- 11:45 – 12:10 *Microparticles as biomarker*
TBD
- 12:10 – 12:35 *Keratins as biomarkers*
Heike Bantel, Germany
- 12:35 – 14:00 Lunch and Sympo?**

6. BILE ACIDS, BILE ACID SIGNALING: BILE ACIDS AS PROGNOSTIC SIGNATURE IN NASH

Chairs: Cecilia Rodrigues, Portugal

Michael Trauner, Austria

- 14:00 – 14:25 *Academic overview*
Michael Trauner, Austria
- 14:25 – 14:50 *Bile acids as prognostic signature in NASH*
Marco Arrese, Chile
- 14:50 – 15:15 *FXR – steroidal agonists*
Luciano Adorini, Italy
- 15:15 – 15:40 *FXR – non- steroidal agonists*
Nikolai Naoumov, Switzerland
- 15:40 – 16:05 *FGF-19 (FXR downstream target)*
Matias Avila, Spain
- 16:05 – 16:30 *ASBT inhibitors*
Hanns-Ulrich Marschall, Sweden
- 16:30 – 17:00 Coffee break and ePoster session 6**

7. GUT MICROBIOTA

Chairs: Tom Karlsen, Norway

Bernd Schnabl, United States

- 17:10 – 17:25 *Academic overview*
Bernd Schnabl, United States
- 17:25 – 17:50 *Microbiome as prognostic signature*
Stanislav Dusko Ehrlich, France (TBC)
- 17:50 – 18:15 *Microbiota and FXR signaling in NAFLD and obesity, to induce or not to induce – that is the question*
Annika Wahlström, Sweden
- 18:15 – 18:40 *Probiotic interventions*
Vanessa Stadlbauer-Köllner, Austria

DAY 3 – Saturday 11 November 2017

8. CARCINOGENESIS

Chairs: Jean-François Dufour, Switzerland
Claus Hellerbrand, Germany

- 08:30 – 08:55 *Academic overview: NASH as fertile soil for HCC, including challenge of pre-cirrhotic HCC*
Jean-François Dufour, Switzerland
- 08:55 – 09:20 *MiRNA as biomarker and target*
Cecilia Rodrigues, Portugal
- 09:20 – 09:45 *Circulating tumour (stem) cells and liquid biopsy*
Mathias Heikenwälder, Germany
- 09:45 – 10:10 *Autophagy - linking alcohol and nutrition in NAFLD progression to cancer*
Claus Hellerbrand, Germany
- 10:10 – 10:35 *Liver histology for biomarker and target discovery*
Peter Schirmacher, Germany
- 10:35 – 11:00 Coffee break and ePoster session 7**

9. FIBROSIS

Chairs: Ali Canbay, Germany
Claus Hellerbrand, Germany
Wing-Kin Syn, United States
Michael Trauner, Austria

- 11:00 – 11:25 *Academic overview*
Massimo Pinzani, United Kingdom
- 11:25 – 11:50 *Fibrosis as prognostically relevant signature: – do we have to care about differentiating NASH from NAFL (or just fibrosis)*
Mattias Ekstedt, Sweden
- 11:50 – 12:15 *How to non-invasively assess fibrosis (serum, transient elastography, MRE)*
Laurent Castera, France
- 12:15 – 12:40 *Targeting liver fibrosis: have we been listening to this song for too long now? (industry perspective)*
Matthias Ocker, Germany
- 12:40 – 13:05 *LOXL-2: single target (fibrosis resolution) or key for combination therapies?*
Robert Myers, United States (TBC)
- 13:05 – 13:30 *What is needed for drug approval? (Regulatory readouts from fibrosis studies)*
Arun Sanyal, United States
- 13:30 – 13:45 Concluding Remarks**